| | Your missing links are here Top Picks Research - Researchers in Spain target fusion oncogenes in cancer cells with CRISPR-Cas9. Targeting these tumour-specific genes is an attractive approach to tackling cancer, and the researchers show proof-of-concept for this strategy in mice that developed tumours following injection with a human Ewing sarcoma cell line.
Industry - Biotech stocks surged on Wednesday following the announcement of this year’s Nobel Prize in Chemistry to CRISPR pioneers Emmanuelle Charpentier and Jennifer A. Doudna. Among the big players, Intellia Therapeutics, Editas Medicine, and Beam Therapeutics went up by 13%, 11%, and 6% respectively, and CRISPR Therapeutics, co-founded by Emmanuelle Charpentier, was also up by more than 11% as of Wednesday morning (7th Oct).
- Sherlock Biosciences, the first company to obtain FDA approval for a CRISPR-based product (SHERLOCK) earlier this year now launches 221b Foundation to address the COVID-19 pandemic and equity in science, technology, engineering, and math (STEM). Simply put, profits from Sherlock’s (or any 3rd party) sales of SHERLOCK CRISPR COVID-19 products will be put into the new foundation to support racial and gender diversity in the STEM areas.
Delivery & Safety COVID-19 Reviews and Opinion Awards & Funding | | |
| | CRISPR Medicine Jobs is Here! We recently launched the first targeted recruitment platform for CRISPR-related jobs. Prospective employers and job seekers from all over the world can use this unique platform to find highly skilled scientists and exciting jobs within the CRISPR Medicine field! Check out the first external job posting from the Hendel Lab in Isreal right here. | | |
| | Thank you for now - more great reads are on the way! And if you have questions or suggestions, you can reach out to us directly at editor@crisprmedicinenews.com. We love hearing from readers! Happy Reading! Karen p.s. You can follow CRISPR Medicine News on Twitter and LinkedIn. If someone forwarded this email to you, you can sign up for our newsletter yourself here. | | |
|
|